Q4 FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Feb 27, 2026
Azitra, Inc. (AZTR) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$3.3 million. As of Jun 30, 2026 it held $6.7 million in cash and investments and $410,053 in total debt.
Revenue
$0
Net income
$-3.35M
-15.9% vs year-ago quarter
Operating cash flow
$-3.29M
-16.9% vs year-ago quarter
Free cash flow
$-3.33M
-17.8% vs year-ago quarter
EPS
$-0.17
+85.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
60.60M
+158.1% vs year-ago quarter
Net cash
$6.32M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AZTR (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Branford, CT
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1701478
- Former names
- Azitra Inc (until Jan 4, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 |
| Operating income | -$3.4M | -$3.9M | -$2.2M | -$2.8M | -$2.9M |
| Net income | -$3.3M | -$3.9M | -$2.2M | -$2.8M | -$2.9M |
| Diluted EPS | -$0.17 | -$0.25 | -$0.21 | -$0.67 | -$1.18 |
| Operating cash flow | -$3.3M | -$2.5M | -$2.9M | -$2.4M | -$2.8M |
| Free cash flow | -$3.3M | -$2.5M | -$2.9M | -$2.4M | -$2.8M |
| Total assets | $8.9M | $12.1M | $5.0M | $4.3M | $4.0M |
| Total liabilities | $1.6M | $1.6M | $1.2M | $2.0M | $1.7M |
| Stockholders' equity | $7.3M | $10.5M | $3.8M | $2.3M | $2.2M |
| Cash and investments | $6.7M | $10.1M | $2.1M | $1.4M | $1.0M |
| Total debt | $410,053 | $343,330 | $422,077 | $499,687 | $577,859 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Other events
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Oct 22, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Other events
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 28, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
All 237 Azitra, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.